BOLD Longevity Growth (BLG) is a newly launched growth-stage biotechnology fund under BOLD Capital, founded by longevity pioneers Peter Diamandis and Sergey Young. BLG focuses on translating deep biological insight into clinically and commercially meaningful therapeutics for age-related disease, backing companies with clear mechanistic grounding, strong translational logic, and credible paths to human proof-of-concept. We partner closely with founders to de-risk science, refine clinical strategy, and build durable, category-defining companies targeting the fundamental drivers of aging, chronic disease, and biological resilience.